[144] Incyte Genomics Inc SEC Filing

Rhea-AI Filing Summary

Incyte Corp. (INCY) filed a Form 144 indicating a proposed sale of 8,617 common shares through Morgan Stanley Smith Barney on or about 03 Jul 2025. The shares have an aggregate market value of $587,272 and represent roughly 0.004% of the 193.57 million shares currently outstanding, signalling a relatively small disposal in percentage terms.

The shares were recently acquired on 02 Jul 2025 via two equity-based awards: 5,935 performance shares and 2,682 restricted shares. The filer reported no other sales in the past three months, and no 10b5-1 plan date was disclosed. The notice includes the standard representation that the seller possesses no undisclosed material adverse information about the company.

Insights

Securities Analyst

TL;DR Insider plans to sell 8.6k INCY shares (<0.01%) worth $0.59 M; negligible ownership impact.

The Form 144 filing signals a modest insider transaction: 8,617 shares valued at about $587 k versus 193.6 M shares outstanding. The sale, routed through Morgan Stanley Smith Barney, is scheduled for early July. Because the stake is immaterial to float size and follows recent equity-award vesting, the filing does not materially alter the investment thesis. However, investors may view any insider sale—particularly soon after share vesting—as a mild sentiment negative. No pattern of continuous selling is indicated, as the filer reports zero sales in the prior quarter. Overall impact is neutral.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	8617	587272.00	193569934	07/03/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/02/2025	Performance Shares	Issuer			5935	07/02/2025	Not Applicable
Common	07/02/2025	Restricted Stock	Issuer			2682	07/02/2025	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Incyte (INCY) shares are being sold under this Form 144?

The notice covers 8,617 common shares of Incyte Corporation.

What is the market value of the proposed insider sale?

The aggregate market value is listed as approximately $587,272.

When is the planned sale date for the INCY shares?

The filer intends to sell on or about 07/03/2025.

What percentage of Incyte’s shares outstanding does the sale represent?

The 8,617 shares equal roughly 0.004% of the 193.57 million shares outstanding.

How were the shares acquired by the insider?

They were obtained on 07/02/2025 via performance shares (5,935) and restricted stock (2,682) awards.

Were there any other insider sales in the past three months?

No. The filing states "Nothing to Report" for prior 3-month sales.